The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

A compound:

##STR00001##

wherein X.sup.1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y.sup.1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X.sup.2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH.sub.2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO.sub.2—NH—, and Y.sup.2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, or —CR.sup.1R.sup.2R.sup.3 or alternatively X.sup.2—Y.sup.2 represents —CONR.sub.cR.sub.d, wherein R.sub.c and R.sub.d form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C.sub.1-C.sub.4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments. ##STR00001##

The present disclosure relates to a benzamide compound as shown in Formula I, an insecticidal comprising same, and a use of the compound as an insecticide in the fields of agriculture, forestry and health.

##STR00001##

The present disclosure relates to a benzamide compound as shown in Formula I, an insecticidal comprising same, and a use of the compound as an insecticide in the fields of agriculture, forestry and health.

##STR00001##

Disclosed is a compound of formula (I): ##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

A compound of formula (Ie):

##STR00001##

wherein Y.sup.1 represents an aryl group, X.sup.2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH.sub.3)NH— group, a —C(OH)(CH.sub.2OH)—, a

##STR00002##

group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO.sub.2— group, or a —SO.sub.2—NH— group, Y.sup.2 represents a hydrogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a —CHC(OH).sub.2, a COOR.sub.f, wherein R.sub.f represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, a morpholinyl group, a dihydropyranyl group, a

##STR00003##

group, a

##STR00004##

group, a —PO(OR.sub.f)(OR′.sub.f) group, wherein R.sub.f and R′.sub.f independently represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, an oxetanyl group, a —Si(CH.sub.3).sub.3 group, a —NHCOO—(C.sub.1-C.sub.4)alkyl group, or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

A compound of formula (Ie):

##STR00001##

wherein Y.sup.1 represents an aryl group, X.sup.2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH.sub.3)NH— group, a —C(OH)(CH.sub.2OH)—, a

##STR00002##

group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO.sub.2— group, or a —SO.sub.2—NH— group, Y.sup.2 represents a hydrogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a —CHC(OH).sub.2, a COOR.sub.f, wherein R.sub.f represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, a morpholinyl group, a dihydropyranyl group, a

##STR00003##

group, a

##STR00004##

group, a —PO(OR.sub.f)(OR′.sub.f) group, wherein R.sub.f and R′.sub.f independently represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, an oxetanyl group, a —Si(CH.sub.3).sub.3 group, a —NHCOO—(C.sub.1-C.sub.4)alkyl group, or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

An aromatic amine compound capable of satisfactorily forming a cured product having exceptional alkali resistance by reaction with an epoxy compound; a curing agent for an epoxy compound, the curing agent including the aromatic amine compound; a curable composition including the curing agent for an epoxy compound; a cured product of the curable composition; a method for producing the cured product; and a method for producing the abovementioned aromatic amine compound. The aromatic amine compound has a structure such that a specific position in a central skeleton comprising a fused ring such as a fluorene ring is substituted with a side-chain group including two aromatic groups linked by a flexible bond such as an amide bond, at least one amino group is bonded to the end of the side-chain group, and the structure has no hydroxyl groups.

An aromatic amine compound capable of satisfactorily forming a cured product having exceptional alkali resistance by reaction with an epoxy compound; a curing agent for an epoxy compound, the curing agent including the aromatic amine compound; a curable composition including the curing agent for an epoxy compound; a cured product of the curable composition; a method for producing the cured product; and a method for producing the abovementioned aromatic amine compound. The aromatic amine compound has a structure such that a specific position in a central skeleton comprising a fused ring such as a fluorene ring is substituted with a side-chain group including two aromatic groups linked by a flexible bond such as an amide bond, at least one amino group is bonded to the end of the side-chain group, and the structure has no hydroxyl groups.